Eli Lilly Warns of Counterfeit Tirzepatide: How to Stay Safe

Eli Lilly issued a public open letter in early 2026 warning that fraudulent products claiming to be Mounjaro, Zepbound, or FDA-approved tirzepatide are circulating widely in the US market. The company's testing laboratory analyzed samples obtained from suspected counterfeit sources, and the results were alarming.

Bacterial contamination was found in multiple samples — products that patients were injecting subcutaneously. Injecting bacterially contaminated products can cause injection site infections, abscesses, sepsis, and in severe cases, life-threatening systemic infections.

Chemical structure deviations were detected in some samples — molecules that resembled tirzepatide but were not identical. Modified peptide structures can have unpredictable pharmacological effects, ranging from complete inefficacy to unexpected toxicity.

High impurity levels exceeding safe pharmaceutical thresholds were common. Peptide synthesis produces byproducts that must be removed through purification processes. Counterfeit manufacturers often skip or abbreviate purification, resulting in products containing synthesis byproducts, degradation products, and potentially toxic impurities.

In at least one case, only sugar alcohol was found — meaning patients were injecting a completely inert substance, paying premium prices for no therapeutic effect, and potentially delaying effective treatment for serious conditions like diabetes or obesity.

The company is pursuing legal action against sellers and has established partnerships with the FDA's Office of Criminal Investigations to identify and shut down counterfeit supply chains.

The counterfeit tirzepatide problem is driven by the convergence of massive demand, high prices, and supply constraints — a combination that creates ideal conditions for counterfeiting.

Market dynamics. Tirzepatide (as Mounjaro and Zepbound) has experienced extraordinary demand since launch, frequently outstripping Eli Lilly's production capacity. When patients cannot obtain legitimate product through their pharmacy — or cannot afford it — some turn to alternative sources, including online sellers, social media marketplaces, and international sources. Many of these alternative channels operate outside pharmaceutical regulatory oversight.

The compounding gray area. During the FDA's shortage declaration for tirzepatide, compounding pharmacies were legally permitted to produce compounded versions. This created a legitimate alternative supply chain, but it also provided cover for less scrupulous operators to sell products of questionable quality under the guise of "compounded" tirzepatide. As the shortage resolves, the legal basis for compounded tirzepatide may narrow, but the demand — and the counterfeit supply — will likely persist.

International sources. Tirzepatide sold through international online pharmacies, particularly those based in countries with less pharmaceutical regulatory oversight, carries additional risks. These products may be genuine but diverted, genuine but improperly stored (peptides are temperature-sensitive), or entirely fraudulent.

Social media marketplace. An increasingly concerning trend is the sale of purported tirzepatide through social media platforms (Instagram, TikTok, Facebook Marketplace). These sellers typically have no pharmacy license, no quality testing, and no accountability. Products obtained through these channels have the highest risk of being counterfeit.

Protecting yourself from counterfeit tirzepatide requires vigilance and adherence to established pharmaceutical supply chains.

FDA-approved product sources. Genuine Mounjaro and Zepbound should only be obtained from licensed retail pharmacies with a valid prescription, mail-order pharmacies verified through your insurance plan, the LillyDirect program (verified supply at $299/month for the starting dose of Zepbound), and healthcare provider offices that dispense medication directly.

Compounded tirzepatide verification. If using a compounding pharmacy, verify PCAB accreditation (the gold standard for compounding quality), request Certificates of Analysis (COA) showing peptide purity (should be greater than 98%), sterility testing results, and endotoxin levels. Confirm the pharmacy is licensed in your state and ask whether they operate under 503A or 503B regulations. 503B outsourcing facilities are subject to stricter FDA oversight.

Red flags for counterfeit products. Be suspicious of prices significantly below market rate (if it seems too good to be true, it is), any source that does not require a valid prescription, products sold through social media, classified ads, or non-pharmacy websites, packaging that differs from official Eli Lilly packaging (check lilly.com for current product images), products shipped without temperature-controlled packaging (tirzepatide requires refrigeration), and any seller who cannot provide pharmacy license information when asked.

What to do if you suspect a counterfeit. Report suspected counterfeit products to the FDA's MedWatch adverse event reporting system and to Eli Lilly directly. If you have administered a suspected counterfeit product and experience adverse effects (injection site infection, unusual symptoms, allergic reactions), seek medical attention immediately.